Data Deficiencies Derail Lifecore Intergel Liquid Adhesion Barrier PMA
This article was originally published in The Gray Sheet
Executive Summary
Higher than expected infection rates, pending safety data and lingering questions over clinical efficacy prompted FDA's General and Plastic Surgery Devices Panel to recommend against approval of Lifecore Biomedical's Intergel adhesion prevention barrier solution in a 5-2 vote during a Jan. 12 meeting in Rockville, Maryland.
You may also be interested in...
FDA Acts Quickly On Lifecore’s Intergel PMA Following Dispute Resolution
FDA has approved Lifecore Biomedical's Gynecare Intergel adhesion prevention solution for the indication sought by the company with the addition of several warnings and contraindications
FDA Acts Quickly On Lifecore’s Intergel PMA Following Dispute Resolution
FDA has approved Lifecore Biomedical's Gynecare Intergel adhesion prevention solution for the indication sought by the company with the addition of several warnings and contraindications
Lifecore Intergel Approvable Despite FDA Objections, MDDR Panel Says
Lifecore Biomedical's Gynecare Intergel adhesion prevention solution appears closer to FDA approval following a determination by the agency's Medical Devices Dispute Resolution Panel (MDDRP) that the firm demonstrated a statistically significant treatment effect.